与普拉衍生抗病毒药物的有效性之间的结构关系
David A Nyenhuis1, Susan Watanabe2, Rebecca Bernstein1
1Biochemistry and Biophysics Center, NHLBI, NIH, 50 South Drive, Bld 50, Rm 3503, Bethesda, MD, 20892, USA.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|March 6, 2024
概括
通过向Tsg101.1,新的期末衍生物抑制病毒的产生. 修改增强了对HIV-1和SARS-CoV-2的疗效,有可能改善药物半衰期和特异性.
科学领域:
- 生物化学 生物化学
- 病毒学 病毒学
- 药用化学 医学化学
背景情况:
- Tsg101是病毒芽的关键宿主因素.
- 普拉衍生物正在研究抗病毒性质.
研究的目的:
- 描述针对Tsg101.1.的期货衍生品.
- 评估它们在抑制病毒颗粒产生方面的有效性.
- 探索结构-活性关系,以增强抗病毒效果.
主要方法:
- 在实验室中对期货衍生品进行表征.
- 对病毒颗粒产生抑制的测试.
- 对Tsg101 adduct形成的分析.
- 结构与活动关系研究.
主要成果:
- 普拉索尔与TSG101的C73部位结合.
- 增加的硬质体量增强了抑制HIV-1病毒样颗粒的产生.
- 形成了新的二次Tsg101 adducts,表明增加了半衰期和特异性.
- 硫化物衍生物显示出有效的病毒抑制,向SARS-CoV-2.
结论:
- 普拉衍生物是有前途的抗病毒药物,针对TSG101.1.
- 结构修改可以优化抗病毒活性并降低毒性.
- 这些化合物的进一步开发可能会导致新的抗病毒疗法.
相关概念视频
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
Structure-Activity Relationships and Drug Design
718
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
718
Antipsychotic Drugs: Typical and Atypical Agents
198
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
198
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K


